SHS verkauft ihre Anteile an Emerging Implant Technologies an Johnson & Johnson

Tuebingen/Tuttlingen — SHS Gesell­schaft fuer Betei­li­gungs­ma­nage­ment, MBG Baden-Würt­­te­m­­berg and VC Fonds BW announ­ced that Emer­ging Implant Tech­no­lo­gies GmbH (EIT), a manu­fac­tu­rer of 3D-prin­­ted tita­nium inter­body implants for spinal fusion surgery, has been acqui­red by John­son & John­son Medi­cal GmbH. SHS became EIT’s lead inves­tor in Septem­ber 2016. Since then the Tuebin­gen based medtech specia­list has subse­quently supported the company’s growth stra­tegy. The finan­cial terms of the deal are undisclosed.

“SHS’s objec­tive was to support EIT on their path to increased growth. This includes the deve­lo­p­ment of the company’s inno­va­tive product port­fo­lio as well as ente­ring new count­ries. We’re deligh­ted to have had such a successful part­ner­ship with EIT and its employees. We look forward to see EIT´s unique products and Cellu­lar Tita­nium® tech­no­logy bene­fit from DePuy Synthes global commer­cial infra­struc­ture and products. We wish EIT all the best in their future deve­lo­p­ment and trust that the company is in good hands with its new owners”, says Dr. Bern­hard Schirm­ers, Mana­ging Part­ner of SHS, lead inves­tor with EIT.

Gunt­mar Eisen, Foun­der and Chief Execu­tive Offi­cer of EIT says: “The EIT team is passio­nate about the work we do every day to deve­lop 3D-prin­­ted tita­nium spinal implants. We are proud of what we have achie­ved with the EIT cellu­lar tita­nium cages and we are exci­ted to bring this inno­va­tive tech­no­logy to DePuy Synthes, and to custo­mers around the world.”

To learn more about the announce­ment, click here: https://www.prnewswire.com/news-releases/johnson–johnson-medical-gmbh-acquires-emerging-implant-technologies-gmbh-to-enhance-global-offering-of-interbody-spine-implants-300710822.html

About SHS Gesell­schaft für Betei­li­gungs­ma­nage­ment mbH
Germany (Tuebin­gen) based SHS Gesell­schaft für Betei­li­gungs­ma­nage­ment was foun­ded in 1993 and invests in medi­cal tech­no­logy and life science compa­nies with a focus on expan­sion finan­cing, chan­ges in share­hol­der struc­tures and succes­sor situa­tions in the DACH-region, Bene­lux-coun­t­ries and Scan­di­na­via. Medi­cal device invest­ments made by the sector specia­list SHS include for exam­ple German company phenox, which specia­li­zes in tech­no­lo­gies for the treat­ment of neuro­vas­cu­lar dise­a­ses, Austrian reha­bi­li­ta­tion robo­tics company Tyro­mo­tion, and the Swiss manu­fac­tu­rer of cardio­logy products SIS Medi­cal. In its fifth fund’s first closing in July 2018 SHS has recei­ved capi­tal commit­ments of over €90 million. Inves­tors can invest in SHS V until final closing (target €150 million). The company invests up to 30 million euro in equity. Rein­hilde Spat­scheck, Dr. Bern­hard Schirm­ers, Huber­tus Leon­hardt and Uwe Stein­ba­cher are the Mana­ging Part­ners at SHS.